The group’s biggest claims were largely incorrect, a New York Times analysis found. And its many smaller cuts added up to few ...
An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback